Influence  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
adding  ||| S:13 E:20 ||| VBG
etravirine  ||| S:20 E:31 ||| NN
on  ||| S:31 E:34 ||| IN
complexity  ||| S:34 E:45 ||| JJ
index  ||| S:45 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
patients ||| S:55 E:63 ||| NNS
'  ||| S:63 E:65 ||| POS
perceived  ||| S:65 E:75 ||| JJ
complexity  ||| S:75 E:86 ||| NN
Adherence  ||| S:86 E:96 ||| NNS
to  ||| S:96 E:99 ||| TO
highly  ||| S:99 E:106 ||| RB
active  ||| S:106 E:113 ||| JJ
antiretroviral  ||| S:113 E:128 ||| JJ
treatment  ||| S:128 E:138 ||| NN
( ||| S:138 E:139 ||| -LRB-
HAART ||| S:139 E:144 ||| NNP
)  ||| S:144 E:146 ||| -RRB-
is  ||| S:146 E:149 ||| VBZ
an  ||| S:149 E:152 ||| DT
important  ||| S:152 E:162 ||| JJ
predictive  ||| S:162 E:173 ||| JJ
factor  ||| S:173 E:180 ||| NN
of  ||| S:180 E:183 ||| IN
treatment  ||| S:183 E:193 ||| NN
outcome ||| S:193 E:200 ||| NN
.  ||| S:200 E:202 ||| .
Medication  ||| S:202 E:213 ||| JJ
regimen  ||| S:213 E:221 ||| JJ
complexity  ||| S:221 E:232 ||| NN
can  ||| S:232 E:236 ||| MD
be  ||| S:236 E:239 ||| VB
one  ||| S:239 E:243 ||| CD
of  ||| S:243 E:246 ||| IN
the  ||| S:246 E:250 ||| DT
main  ||| S:250 E:255 ||| JJ
causes  ||| S:255 E:262 ||| NNS
of  ||| S:262 E:265 ||| IN
non-adherence ||| S:265 E:278 ||| JJ
.  ||| S:278 E:280 ||| .
Thus ||| S:280 E:284 ||| RB
,  ||| S:284 E:286 ||| ,
treatment  ||| S:286 E:296 ||| NN
simplification  ||| S:296 E:311 ||| NN
is  ||| S:311 E:314 ||| VBZ
a  ||| S:314 E:316 ||| DT
key  ||| S:316 E:320 ||| JJ
strategy  ||| S:320 E:329 ||| NN
in  ||| S:329 E:332 ||| IN
the  ||| S:332 E:336 ||| DT
development  ||| S:336 E:348 ||| NN
of  ||| S:348 E:351 ||| IN
antiretroviral  ||| S:351 E:366 ||| JJ
therapy ||| S:366 E:373 ||| NN
.  ||| S:373 E:375 ||| .
The  ||| S:375 E:379 ||| DT
aim  ||| S:379 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
this  ||| S:386 E:391 ||| DT
study  ||| S:391 E:397 ||| NN
was  ||| S:397 E:401 ||| VBD
to  ||| S:401 E:404 ||| TO
determine  ||| S:404 E:414 ||| VB
the  ||| S:414 E:418 ||| DT
influence  ||| S:418 E:428 ||| NN
of  ||| S:428 E:431 ||| IN
adding  ||| S:431 E:438 ||| VBG
etravirine  ||| S:438 E:449 ||| NN
on  ||| S:449 E:452 ||| IN
complexity  ||| S:452 E:463 ||| JJ
index  ||| S:463 E:469 ||| NN
and  ||| S:469 E:473 ||| CC
patients ||| S:473 E:481 ||| NNS
'  ||| S:481 E:483 ||| POS
perceived  ||| S:483 E:493 ||| JJ
complexity  ||| S:493 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
their  ||| S:507 E:513 ||| PRP$
treatment  ||| S:513 E:523 ||| NN
regimen ||| S:523 E:530 ||| NN
.  ||| S:530 E:532 ||| .
We  ||| S:532 E:535 ||| PRP
conducted  ||| S:535 E:545 ||| VBD
a  ||| S:545 E:547 ||| DT
prospective  ||| S:547 E:559 ||| JJ
two-centre  ||| S:559 E:570 ||| JJ
observational  ||| S:570 E:584 ||| JJ
study ||| S:584 E:589 ||| NN
.  ||| S:589 E:591 ||| .
Patients  ||| S:591 E:600 ||| NNS
on  ||| S:600 E:603 ||| IN
etravirine-based  ||| S:603 E:620 ||| JJ
therapy ||| S:620 E:627 ||| NN
,  ||| S:627 E:629 ||| ,
for  ||| S:629 E:633 ||| IN
at  ||| S:633 E:636 ||| IN
least  ||| S:636 E:642 ||| JJS
6 months ||| S:642 E:650 ||| CD
,  ||| S:650 E:652 ||| ,
who  ||| S:652 E:656 ||| WP
came  ||| S:656 E:661 ||| VBD
personally  ||| S:661 E:672 ||| RB
to  ||| S:672 E:675 ||| TO
pharmacy  ||| S:675 E:684 ||| VB
departments  ||| S:684 E:696 ||| NNS
for  ||| S:696 E:700 ||| IN
a  ||| S:700 E:702 ||| DT
drug  ||| S:702 E:707 ||| NN
refill  ||| S:707 E:714 ||| NN
from  ||| S:714 E:719 ||| IN
February  ||| S:719 E:728 ||| NNP
to  ||| S:728 E:731 ||| TO
July  ||| S:731 E:736 ||| NNP
2012  ||| S:736 E:741 ||| CD
were  ||| S:741 E:746 ||| VBD
included ||| S:746 E:754 ||| VBN
.  ||| S:754 E:756 ||| .
Data  ||| S:756 E:761 ||| NNP
were  ||| S:761 E:766 ||| VBD
collected  ||| S:766 E:776 ||| VBN
for  ||| S:776 E:780 ||| IN
the  ||| S:780 E:784 ||| DT
current  ||| S:784 E:792 ||| JJ
etravirine-based  ||| S:792 E:809 ||| JJ
HAART  ||| S:809 E:815 ||| NNP
and  ||| S:815 E:819 ||| CC
for  ||| S:819 E:823 ||| IN
the  ||| S:823 E:827 ||| DT
previous  ||| S:827 E:836 ||| JJ
HAART  ||| S:836 E:842 ||| NN
without  ||| S:842 E:850 ||| IN
etravirine ||| S:850 E:860 ||| NN
.  ||| S:860 E:862 ||| .
The  ||| S:862 E:866 ||| DT
main  ||| S:866 E:871 ||| JJ
variables  ||| S:871 E:881 ||| NNS
were  ||| S:881 E:886 ||| VBD
complexity  ||| S:886 E:897 ||| JJ
index  ||| S:897 E:903 ||| NN
and  ||| S:903 E:907 ||| CC
patients ||| S:907 E:915 ||| NNS
'  ||| S:915 E:917 ||| POS
perceived  ||| S:917 E:927 ||| JJ
complexity ||| S:927 E:937 ||| NN
.  ||| S:937 E:939 ||| .
We  ||| S:939 E:942 ||| PRP
also  ||| S:942 E:947 ||| RB
evaluated  ||| S:947 E:957 ||| VBN
the  ||| S:957 E:961 ||| DT
adherence  ||| S:961 E:971 ||| NN
during  ||| S:971 E:978 ||| IN
the  ||| S:978 E:982 ||| DT
6 months  ||| S:982 E:991 ||| NN
before  ||| S:991 E:998 ||| IN
and  ||| S:998 E:1002 ||| CC
after  ||| S:1002 E:1008 ||| IN
the  ||| S:1008 E:1012 ||| DT
introduction  ||| S:1012 E:1025 ||| NN
of  ||| S:1025 E:1028 ||| IN
etravirine  ||| S:1028 E:1039 ||| NN
into  ||| S:1039 E:1044 ||| IN
HAART ||| S:1044 E:1049 ||| NNP
.  ||| S:1049 E:1051 ||| .
The  ||| S:1051 E:1055 ||| DT
complexity  ||| S:1055 E:1066 ||| NN
index  ||| S:1066 E:1072 ||| NN
was  ||| S:1072 E:1076 ||| VBD
based  ||| S:1076 E:1082 ||| VBN
on  ||| S:1082 E:1085 ||| IN
a  ||| S:1085 E:1087 ||| DT
score  ||| S:1087 E:1093 ||| NN
which  ||| S:1093 E:1099 ||| WDT
takes  ||| S:1099 E:1105 ||| VBZ
into  ||| S:1105 E:1110 ||| IN
account  ||| S:1110 E:1118 ||| NN
the  ||| S:1118 E:1122 ||| DT
number  ||| S:1122 E:1129 ||| NN
of  ||| S:1129 E:1132 ||| IN
pills  ||| S:1132 E:1138 ||| NNS
per  ||| S:1138 E:1142 ||| IN
day ||| S:1142 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
the  ||| S:1147 E:1151 ||| DT
dosing  ||| S:1151 E:1158 ||| JJ
schedule ||| S:1158 E:1166 ||| NN
,  ||| S:1166 E:1168 ||| ,
the  ||| S:1168 E:1172 ||| DT
dosage  ||| S:1172 E:1179 ||| JJ
form  ||| S:1179 E:1184 ||| NN
and  ||| S:1184 E:1188 ||| CC
any  ||| S:1188 E:1192 ||| DT
specific  ||| S:1192 E:1201 ||| JJ
instructions  ||| S:1201 E:1214 ||| NNS
linked  ||| S:1214 E:1221 ||| VBN
to  ||| S:1221 E:1224 ||| TO
use  ||| S:1224 E:1228 ||| VB
of  ||| S:1228 E:1231 ||| IN
the  ||| S:1231 E:1235 ||| DT
drug ||| S:1235 E:1239 ||| NN
.  ||| S:1239 E:1241 ||| .
To  ||| S:1241 E:1244 ||| TO
evaluate  ||| S:1244 E:1253 ||| VB
the  ||| S:1253 E:1257 ||| DT
patients ||| S:1257 E:1265 ||| NNS
'  ||| S:1265 E:1267 ||| POS
perceived  ||| S:1267 E:1277 ||| JJ
complexity  ||| S:1277 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
their  ||| S:1291 E:1297 ||| PRP$
current  ||| S:1297 E:1305 ||| JJ
and  ||| S:1305 E:1309 ||| CC
previous  ||| S:1309 E:1318 ||| JJ
HAART ||| S:1318 E:1323 ||| NNP
,  ||| S:1323 E:1325 ||| ,
patients  ||| S:1325 E:1334 ||| NNS
were  ||| S:1334 E:1339 ||| VBD
asked  ||| S:1339 E:1345 ||| VBN
to  ||| S:1345 E:1348 ||| TO
assign  ||| S:1348 E:1355 ||| VB
a  ||| S:1355 E:1357 ||| DT
mark  ||| S:1357 E:1362 ||| NN
on  ||| S:1362 E:1365 ||| IN
a  ||| S:1365 E:1367 ||| DT
visual  ||| S:1367 E:1374 ||| JJ
analogue  ||| S:1374 E:1383 ||| JJ
scale  ||| S:1383 E:1389 ||| NN
ranging  ||| S:1389 E:1397 ||| VBG
from  ||| S:1397 E:1402 ||| IN
0  ||| S:1402 E:1404 ||| CD
( ||| S:1404 E:1405 ||| -LRB-
minimum ||| S:1405 E:1412 ||| NN
)  ||| S:1412 E:1414 ||| -RRB-
to  ||| S:1414 E:1417 ||| TO
10  ||| S:1417 E:1420 ||| CD
( ||| S:1420 E:1421 ||| -LRB-
maximum ||| S:1421 E:1428 ||| NN
) ||| S:1428 E:1429 ||| -RRB-
.  ||| S:1429 E:1431 ||| .
We  ||| S:1431 E:1434 ||| PRP
assessed  ||| S:1434 E:1443 ||| VBD
the  ||| S:1443 E:1447 ||| DT
differences  ||| S:1447 E:1459 ||| NNS
in  ||| S:1459 E:1462 ||| IN
the  ||| S:1462 E:1466 ||| DT
variables  ||| S:1466 E:1476 ||| NNS
collected  ||| S:1476 E:1486 ||| VBN
between  ||| S:1486 E:1494 ||| IN
the  ||| S:1494 E:1498 ||| DT
current  ||| S:1498 E:1506 ||| JJ
and  ||| S:1506 E:1510 ||| CC
previous  ||| S:1510 E:1519 ||| JJ
antiretroviral  ||| S:1519 E:1534 ||| JJ
therapy ||| S:1534 E:1541 ||| NN
.  ||| S:1541 E:1543 ||| .
Finally ||| S:1543 E:1550 ||| RB
,  ||| S:1550 E:1552 ||| ,
we  ||| S:1552 E:1555 ||| PRP
carried  ||| S:1555 E:1563 ||| VBD
out  ||| S:1563 E:1567 ||| RP
a  ||| S:1567 E:1569 ||| DT
correlation  ||| S:1569 E:1581 ||| JJ
analysis  ||| S:1581 E:1590 ||| NN
between  ||| S:1590 E:1598 ||| IN
the  ||| S:1598 E:1602 ||| DT
complexity  ||| S:1602 E:1613 ||| NN
index  ||| S:1613 E:1619 ||| NN
and  ||| S:1619 E:1623 ||| CC
the  ||| S:1623 E:1627 ||| DT
patients ||| S:1627 E:1635 ||| NNS
'  ||| S:1635 E:1637 ||| POS
perceived  ||| S:1637 E:1647 ||| JJ
complexity ||| S:1647 E:1657 ||| NN
.  ||| S:1657 E:1659 ||| .
Eighty  ||| S:1659 E:1666 ||| JJ
patients  ||| S:1666 E:1675 ||| NNS
were  ||| S:1675 E:1680 ||| VBD
included ||| S:1680 E:1688 ||| VBN
.  ||| S:1688 E:1690 ||| .
The  ||| S:1690 E:1694 ||| DT
complexity  ||| S:1694 E:1705 ||| NN
index  ||| S:1705 E:1711 ||| NN
was  ||| S:1711 E:1715 ||| VBD
significantly  ||| S:1715 E:1729 ||| RB
reduced  ||| S:1729 E:1737 ||| VBN
after  ||| S:1737 E:1743 ||| IN
the  ||| S:1743 E:1747 ||| DT
addition  ||| S:1747 E:1756 ||| NN
of  ||| S:1756 E:1759 ||| IN
etravirine  ||| S:1759 E:1770 ||| VBG
to  ||| S:1770 E:1773 ||| TO
HAART  ||| S:1773 E:1779 ||| NNP
( ||| S:1779 E:1780 ||| -LRB-
P = 0·035 ||| S:1780 E:1789 ||| NNP
) ||| S:1789 E:1790 ||| -RRB-
.  ||| S:1790 E:1792 ||| .
Perceived  ||| S:1792 E:1802 ||| JJ
complexity  ||| S:1802 E:1813 ||| NN
was  ||| S:1813 E:1817 ||| VBD
also  ||| S:1817 E:1822 ||| RB
reduced  ||| S:1822 E:1830 ||| VBN
( ||| S:1830 E:1831 ||| -LRB-
P = 0·015 ||| S:1831 E:1840 ||| NNP
) ||| S:1840 E:1841 ||| -RRB-
.  ||| S:1841 E:1843 ||| .
After  ||| S:1843 E:1849 ||| IN
the  ||| S:1849 E:1853 ||| DT
introduction  ||| S:1853 E:1866 ||| NN
of  ||| S:1866 E:1869 ||| IN
the  ||| S:1869 E:1873 ||| DT
drug ||| S:1873 E:1877 ||| NN
,  ||| S:1877 E:1879 ||| ,
the  ||| S:1879 E:1883 ||| DT
proportion  ||| S:1883 E:1894 ||| NN
of  ||| S:1894 E:1897 ||| IN
adherent  ||| S:1897 E:1906 ||| JJ
patients  ||| S:1906 E:1915 ||| NNS
increased  ||| S:1915 E:1925 ||| VBN
from  ||| S:1925 E:1930 ||| IN
65 ||| S:1930 E:1932 ||| CD
%  ||| S:1932 E:1934 ||| NN
to  ||| S:1934 E:1937 ||| TO
81·3 ||| S:1937 E:1941 ||| CD
%  ||| S:1941 E:1943 ||| NN
( ||| S:1943 E:1944 ||| -LRB-
P = 0·002 ||| S:1944 E:1953 ||| NNP
) ||| S:1953 E:1954 ||| -RRB-
.  ||| S:1954 E:1956 ||| .
The  ||| S:1956 E:1960 ||| DT
correlation  ||| S:1960 E:1972 ||| NN
between  ||| S:1972 E:1980 ||| IN
the  ||| S:1980 E:1984 ||| DT
complexity  ||| S:1984 E:1995 ||| NN
index  ||| S:1995 E:2001 ||| NN
and  ||| S:2001 E:2005 ||| CC
the  ||| S:2005 E:2009 ||| DT
patients ||| S:2009 E:2017 ||| NNS
'  ||| S:2017 E:2019 ||| POS
perceived  ||| S:2019 E:2029 ||| JJ
complexity  ||| S:2029 E:2040 ||| NN
was  ||| S:2040 E:2044 ||| VBD
positive  ||| S:2044 E:2053 ||| JJ
( ||| S:2053 E:2054 ||| -LRB-
r = 0·594 ||| S:2054 E:2063 ||| NNP
) ||| S:2063 E:2064 ||| -RRB-
.  ||| S:2064 E:2066 ||| .
The  ||| S:2066 E:2070 ||| DT
correlation  ||| S:2070 E:2082 ||| NN
increased  ||| S:2082 E:2092 ||| VBD
( ||| S:2092 E:2093 ||| -LRB-
r = 0·696 ||| S:2093 E:2102 ||| NNP
)  ||| S:2102 E:2104 ||| -RRB-
when  ||| S:2104 E:2109 ||| WRB
the  ||| S:2109 E:2113 ||| DT
difference  ||| S:2113 E:2124 ||| NN
between  ||| S:2124 E:2132 ||| IN
the  ||| S:2132 E:2136 ||| DT
complexity  ||| S:2136 E:2147 ||| NN
index  ||| S:2147 E:2153 ||| NN
before  ||| S:2153 E:2160 ||| IN
and  ||| S:2160 E:2164 ||| CC
after  ||| S:2164 E:2170 ||| IN
the  ||| S:2170 E:2174 ||| DT
introduction  ||| S:2174 E:2187 ||| NN
of  ||| S:2187 E:2190 ||| IN
etravirine  ||| S:2190 E:2201 ||| NN
in  ||| S:2201 E:2204 ||| IN
HAART  ||| S:2204 E:2210 ||| NNP
grew ||| S:2210 E:2214 ||| VBD
.  ||| S:2214 E:2216 ||| .
The  ||| S:2216 E:2220 ||| DT
addition  ||| S:2220 E:2229 ||| NN
of  ||| S:2229 E:2232 ||| IN
etravirine  ||| S:2232 E:2243 ||| VBG
to  ||| S:2243 E:2246 ||| TO
HAART  ||| S:2246 E:2252 ||| NNP
results  ||| S:2252 E:2260 ||| NNS
in  ||| S:2260 E:2263 ||| IN
a  ||| S:2263 E:2265 ||| DT
significant  ||| S:2265 E:2277 ||| JJ
reduction  ||| S:2277 E:2287 ||| NN
in  ||| S:2287 E:2290 ||| IN
complexity  ||| S:2290 E:2301 ||| JJ
index  ||| S:2301 E:2307 ||| NN
and  ||| S:2307 E:2311 ||| CC
patients ||| S:2311 E:2319 ||| NNS
'  ||| S:2319 E:2321 ||| POS
perceived  ||| S:2321 E:2331 ||| JJ
complexity  ||| S:2331 E:2342 ||| NN
of  ||| S:2342 E:2345 ||| IN
their  ||| S:2345 E:2351 ||| PRP$
therapy ||| S:2351 E:2358 ||| NN
.  ||| S:2358 E:2360 ||| .
These  ||| S:2360 E:2366 ||| DT
changes  ||| S:2366 E:2374 ||| NNS
were  ||| S:2374 E:2379 ||| VBD
associated  ||| S:2379 E:2390 ||| VBN
with  ||| S:2390 E:2395 ||| IN
better  ||| S:2395 E:2402 ||| JJR
adherence  ||| S:2402 E:2412 ||| NN
to  ||| S:2412 E:2415 ||| TO
treatment ||| S:2415 E:2424 ||| NN
.  ||| S:2424 E:2426 ||| .
